Clinical Trial Update: Topotecan Weekly Versus Topotecan Day 1-5 in Patient With Platin-resistant Ovarian Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial comparing weekly topotecan to a day 1-5 dosing schedule in platinum-resistant ovarian cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Topotecan (topotecan)

Snippet

Sponsor: North Eastern German Society of Gynaecological Oncology | Conditions: Ovarian Cancer | Phase 2 | Status: COMPLETED